January 3, 2019

Syros to Present at 37th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview, including 2019 objectives, at the 37th Annual J.P. Morgan Healthcare Conference. Details are as follows:

37th Annual J.P. Morgan Healthcare Conference
Date: Thursday, January 10
Time: 9:00 a.m. PST (12:00 p.m. EST)
Location: Westin St. Francis Hotel, 335 Powell St., San Francisco, CA

The presentation will be followed by a question and answer session.

Live webcasts of the presentation and question and answer session will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of both webcasts will be available for approximately 30 days.

About Syros Pharmaceuticals

Syros is pioneering the understanding of the non-coding regulatory region of the genome to advance a new wave of medicines that control the expression of genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros' gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and monogenic diseases and is advancing a growing pipeline of gene control medicines. Syros' lead drug candidates are SY-1425, a selective RARα agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial for patients with ovarian and breast cancers. Syros is also developing a deep preclinical and discovery pipeline, including SY-5609, an oral CDK7 inhibitor, as well as programs in immuno-oncology and sickle cell disease. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.

View source version on businesswire.com:
https://www.businesswire.com/news/home/20190103005005/en/

Media Contact:
Naomi Aoki
Syros Pharmaceuticals

617-283-4298
naoki@syros.com

Investor Contact:
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannahd@sternir.com

Source: Syros Pharmaceuticals